TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
This Quarter Return
+9.11%
1 Year Return
+18.15%
3 Year Return
+62.34%
5 Year Return
+140.22%
10 Year Return
+499.57%
AUM
$2.4B
AUM Growth
+$2.4B
(+12%)
Cap. Flow
+$85.1M
Cap. Flow
% of AUM
3.55%
Top 10 Holdings %
Top 10 Hldgs %
48.18%
Holding
111
New
19
Increased
30
Reduced
16
Closed
10
Top Buys
| 1 |
Teva Pharmaceuticals
TEVA
|
$35.8M |
| 2 |
AbbVie
ABBV
|
$30.2M |
| 3 |
AGN
Allergan plc
AGN
|
$25M |
| 4 |
Baxter International
BAX
|
$21.9M |
| 5 |
Gilead Sciences
GILD
|
$19.5M |
Top Sells
| 1 |
SHPG
Shire pic
SHPG
|
$59.8M |
| 2 |
AGN
ALLERGAN INC
AGN
|
$48.5M |
| 3 |
Vertex Pharmaceuticals
VRTX
|
$28M |
| 4 |
NPSP
NPS PHARMACEUTICALS INC
NPSP
|
$22.4M |
| 5 |
Neurocrine Biosciences
NBIX
|
$19.8M |
Sector Composition
| 1 | Healthcare | 84.29% |
| 2 | Real Estate | 4.15% |
| 3 | Financials | 1.47% |
| 4 | Industrials | 0.11% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
101
Ligand Pharmaceuticals
LGND
$3.25B
| – | – |
-69,200
| Closed | -$3.68M |
|
102
Eli Lilly
LLY
$661B
| – | – |
-186,918
| Closed | -$12.9M |
|
103
MEI Pharma
MEIP
$149M
| – | – |
-243,920
| Closed | -$1.04M |
|
104
PTC Therapeutics
PTCT
$4.41B
| – | – |
-119,150
| Closed | -$6.17M |
|
|
EIGR
105
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
| – | – |
-606,482
| Closed | -$11.8M |
|
|
CLVS
106
DELISTED
Clovis Oncology, Inc.
CLVS
| – | – |
-51
| Closed | -$3K |
|
|
DRNA
107
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| – | – |
-156,250
| Closed | -$2.57M |
|